Notice Regarding the Continuation of the Company’s Response Policy for Large-Scale Purchases of Shares or Other Securities in Light of Dalton and Others’ Large-Scale Purchase of the Company’s Shares or Other Securities

あすか製薬ホールディングス confirmed that, even after Dalton and others withdrew their large-scale purchase of shares or other securities, it would not abolish the response policy for large-scale purchases already introduced and would maintain it through its prescribed effective period.

Worth reading

13Immaterial

Scored from 4 of 5 sections

Direction

Neutral

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Avoiding a definitive answer

How definitive the wording is.

This transaction

大規模買付行為等に関する対応方針の存続

Counterpartyダルトンら

Disclosing companyASKA Pharmaceutical Holdings Co.,Ltd.

Subject of this transaction

This transaction
Item	Details
Transaction name	大規模買付行為等に関する対応方針の存続
Counterparty name	ダルトンら

Items this document does not state (30)

Name of the Subject CompanyBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceDate of board resolutionContract DateExecution Date / Effective DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

ダルトンらが自己利益の追求のみを目的として株式をさらに買い増し、一般株主との利益相反や当社の中長期的な企業価値・株主共同の利益の毀損につながる懸念が依然として解消していないため。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.